Plus Therapeutics grants options and RSUs to CDO

PLUS THERAPEUTICS, INC. granted Chief Development Officer Eric Joseph Daniels equity-based compensation.

Rhea-AI Filing Summary

PLUS THERAPEUTICS, INC. granted Chief Development Officer Eric Joseph Daniels equity-based compensation. He received stock options covering 20,000 shares of Common Stock at an exercise price of $7.30 per share, expiring on April 19, 2036. One fourth of these options vest on April 20, 2027, with the remaining options vesting in substantially equal monthly installments over the following 36 months.

Daniels was also awarded 20,000 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock. One third of the RSUs vest on July 1, 2027, and the remaining RSUs vest ratably over the next eight quarters in substantially equal increments. These awards are compensation grants rather than open-market purchases or sales.

Insider Trade Summary

Grant/Award: 40,000 shares

Grant/Award 2 txns

Insider Daniels Eric Joseph

Role Chief Development Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	20,000	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	20,000	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 20,000 contracts (Direct); Stock Option (Right to Buy) — 20,000 contracts (Direct)

Footnotes (2)

1. F1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. One third of the RSUs awarded vest on July 1, 2027, and the remainder of the RSUs vest ratably over the next eight quarters in substantially equal increments.
2. F2. One fourth of the options vest on April 20, 2027 and an additional 1/36th of the remaining options vest on each monthly anniversary thereafter in substantially equal increments.

Key Figures

Stock options granted: 20,000 options Option exercise price: $7.30 per share Option expiration: April 19, 2036 +3 more

6 metrics

Stock options granted 20,000 options Grant to Chief Development Officer on April 20, 2026

Option exercise price $7.30 per share Stock Option (Right to Buy) for Common Stock

Option expiration April 19, 2036 Expiration date of granted stock options

RSUs granted 20,000 RSUs Restricted Stock Units awarded on April 20, 2026

RSU first vesting date July 1, 2027 One third of RSUs vest on this date

Option initial vesting date April 20, 2027 One fourth of options vest on this date

Key Terms

Restricted Stock Units, Stock Option (Right to Buy, vest, Common Stock

4 terms

Restricted Stock Units financial

"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy financial

"Stock Option (Right to Buy) with an exercise price of 7.3000 per share."

vest financial

"One third of the RSUs awarded vest on July 1, 2027, and the remainder vest ratably over the next eight quarters."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Common Stock financial

"Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did PSTV grant to its Chief Development Officer?

PLUS THERAPEUTICS granted Chief Development Officer Eric Joseph Daniels 20,000 stock options and 20,000 Restricted Stock Units (RSUs). Both awards are tied to the company’s Common Stock and vest over multi‑year schedules based on continued service.

What are the key terms of Eric Daniels’ new stock options at PSTV?

Eric Daniels received options on 20,000 shares of Common Stock at an exercise price of $7.30 per share, expiring on April 19, 2036. One fourth vest on April 20, 2027, with remaining options vesting monthly over 36 months.

How do the new RSUs granted to the PSTV Chief Development Officer vest?

Daniels’ 20,000 RSUs each represent a contingent right to one share of Common Stock. One third vest on July 1, 2027, with the remaining units vesting ratably over the next eight quarters in substantially equal increments.

Are Eric Daniels’ new PSTV equity awards open-market share purchases?

No. The Form 4 shows grant/award acquisitions of stock options and RSUs, not open-market purchases or sales. These awards are part of Daniels’ compensation package and vest over time based on continued service with PLUS THERAPEUTICS.

What type of securities underlie Eric Daniels’ new PSTV awards?

Both the stock options and the RSUs for Eric Daniels are linked to PLUS THERAPEUTICS’ Common Stock. Each option grants the right to buy one share at $7.30, and each RSU represents a contingent right to receive one share upon vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/22/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daniels Eric Joseph

(Last) (First) (Middle)

6420 LEVIT GREEN BOULEVARD, SUITE 310

(Street)

HOUSTON TEXAS 77021

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PLUS THERAPEUTICS, INC. [ PSTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(1)	04/20/2026		A		20,000		(1)	(1)	Common Stock	20,000	$0	20,000	D
Stock Option (Right to Buy)	$7.3	04/20/2026		A		20,000		(2)	04/19/2036	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. One third of the RSUs awarded vest on July 1, 2027, and the remainder of the RSUs vest ratably over the next eight quarters in substantially equal increments.

2. One fourth of the options vest on April 20, 2027 and an additional 1/36th of the remaining options vest on each monthly anniversary thereafter in substantially equal increments.

	Andrew Sims, as attorney-in-fact	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)